Breaking News, Collaborations & Alliances

Servier Acquires Day One Biopharmaceuticals, Expanding Rare Oncology Portfolio

The transaction is expected to close in the second quarter of 2026.

Author Image

By: Patrick Lavery

Content Marketing Editor

Servier, an independent international pharmaceutical group, is acquiring Day One Biopharmaceuticals for $21.50 per share in cash. That amounts to a total equity value of approximately $2.5 billion. According to Servier, the offer price represents an approximate 68% premium over Day One’s closing price on March 5, 2026. Moreover, it is a premium of approximately 86% over the one-month volume weighted average of Day One on that date. Servier and Day One Backgrounds Based in France, Servie...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters